DE3750979T2 - 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung in der Behandlung neurodegenerativer Beschwerden. - Google Patents

5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung in der Behandlung neurodegenerativer Beschwerden.

Info

Publication number
DE3750979T2
DE3750979T2 DE3750979T DE3750979T DE3750979T2 DE 3750979 T2 DE3750979 T2 DE 3750979T2 DE 3750979 T DE3750979 T DE 3750979T DE 3750979 T DE3750979 T DE 3750979T DE 3750979 T2 DE3750979 T2 DE 3750979T2
Authority
DE
Germany
Prior art keywords
triazol
aryl
treatment
neurodegenerative
complaints
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3750979T
Other languages
English (en)
Other versions
DE3750979D1 (de
Inventor
Francis P Miller
John M Kane
Stephen Sorensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE3750979D1 publication Critical patent/DE3750979D1/de
Application granted granted Critical
Publication of DE3750979T2 publication Critical patent/DE3750979T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3750979T 1986-12-19 1987-12-17 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung in der Behandlung neurodegenerativer Beschwerden. Expired - Fee Related DE3750979T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94463486A 1986-12-19 1986-12-19
US10700187A 1987-10-16 1987-10-16

Publications (2)

Publication Number Publication Date
DE3750979D1 DE3750979D1 (de) 1995-02-23
DE3750979T2 true DE3750979T2 (de) 1995-05-24

Family

ID=26804275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3750979T Expired - Fee Related DE3750979T2 (de) 1986-12-19 1987-12-17 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung in der Behandlung neurodegenerativer Beschwerden.

Country Status (9)

Country Link
EP (1) EP0273309B1 (de)
JP (1) JP2593084B2 (de)
KR (1) KR880007495A (de)
AT (1) ATE116851T1 (de)
DE (1) DE3750979T2 (de)
DK (1) DK172668B1 (de)
ES (1) ES2069528T3 (de)
GR (1) GR3015685T3 (de)
IE (1) IE65857B1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
MX2007000788A (es) 2004-07-27 2007-03-23 Hoffmann La Roche Compuestos de benciltriazolona como inhibidores no nucleosidos de transcriptasa inversa.
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1126882B (de) * 1960-05-03 1962-04-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 1,2,4-Triazolonen-(5)
BE621842A (de) * 1962-08-27
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
DD153953A3 (de) * 1980-04-01 1982-02-17 Gottfried Schuster Mittel zur chemotherapie von virosen der kulturpflanzen
DD160447A1 (de) * 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
AR243171A1 (es) * 1985-10-29 1993-07-30 Merrell Pharma Inc Procedimiento para preparar 5-aril-2,4-dialquil-3h-1,2,4-triazol-3-tionas.

Also Published As

Publication number Publication date
JPS63170312A (ja) 1988-07-14
DK671187D0 (da) 1987-12-18
EP0273309A3 (de) 1991-01-09
DE3750979D1 (de) 1995-02-23
GR3015685T3 (en) 1995-07-31
IE65857B1 (en) 1995-11-29
JP2593084B2 (ja) 1997-03-19
ATE116851T1 (de) 1995-01-15
KR880007495A (ko) 1988-08-27
DK172668B1 (da) 1999-05-10
DK671187A (da) 1988-06-20
EP0273309A2 (de) 1988-07-06
IE873459L (en) 1989-04-16
EP0273309B1 (de) 1995-01-11
ES2069528T3 (es) 1995-05-16

Similar Documents

Publication Publication Date Title
DE68929540T2 (de) Substituierte Phenylpyrimidine Derivate, für die Behandlung oder Prevention von ZNS-Erkrankungen
FI935585A0 (fi) Pyrrolopyrimidiner
CO4230019A1 (es) Antagonistas de neuroquinina diazabiciclica
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE3852773T2 (de) Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.
DE3750979D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung in der Behandlung neurodegenerativer Beschwerden.
DE68925004T2 (de) Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
ATE105191T1 (de) Orale hyposensibilisierung bei der behandlung von allergien.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee